Statement for the prevention of stroke and systemic embolism in
adult patients with non-valvular atrial fibrillation
The statement for the prevention of stroke and systemic embolism
in adult patients with non-valvular atrial fibrillation and
dabigatran questions and answers are available below.
Dabigatran etexilate (Pradaxa®) and rivaroxaban (Xarelto®)
Healthcare Improvement Scotland has been providing national
leadership and support for safe and effective use of the new oral
anticoagulants, dabigatran etexilate (Pradaxa®) and rivaroxaban
(Xarelto®) in NHSScotland via the development of a
national statement on their use.
The statement identifies those patient groups that should be
considered for dabigatran, rivaroxaban or existing anticoagulants,
such as warfarin.
The statement has been issued via each NHS boards’ Area
Drug and Therapeutic Committee (ADTC).
Share this content
Published Date: 30 April 2012